

ASX Release

26th November 2015

PharmAust Appoints GenScript to Complete Further Pre-Clinical Validation for Phase II Trial

Validation of Synergy between Monepantel and Chemotherapy

PharmAust Limited (“PharmAust”) (ASX: PAA) is pleased to report that it has appointed GenScript to investigate the use of PPL-1/monepantel in conjunction with current “Standard of Care” in preparation for PharmAust’s investigation of monepantel in Phase II.

Following PharmAust’s demonstration that combinations of chemotherapy and monepantel result in synergy with respect to anticancer activity, the company will be investigating and validating the various combinations in different cancers in GenScript’s model systems. This work programme will be as a prelude to PharmAust initiating its Phase II trial.

GenScript is the leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and pre-clinical pharmaceutical development. Since their establishment in 2002, GenScript has exponentially grown to become a global leading biotech company that provides life sciences services and products to scientists over 100 countries worldwide. PharmAust will be accessing their *in vitro* and *in vivo* pharmacology capability to optimised its treatment regiments for the Phase II trial.

GenScript have developed a wide range of validated tumour models based on xenograft models and established a tumour tissue bank with various patient-derived human primary tumour models.

For further details please contact:

Dr. Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

Sam Wright
Director & Company Secretary
Tel: 0408 900 277
sam@pharmaust.com

For personal use only